바이오테크 보도자료
-
- Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
- Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Inn...
- 06월 11일 15:00
-
- Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
- Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,6...
- 06월 11일 09:43
-
- Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
- Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Foo...
- 06월 11일 09:02
-
- Yokogawa Announces Release of Next-Generation of the CENTUM VP Integrated Production Control System
- Yokogawa Electric Corporation (TOKYO: 6841) announces the unveiling of the next-generation Release 7 concept and the launch of Release 7.01 of the CENTUM™ VP integrated production control system, a core prod...
- 06월 10일 11:40
-
- Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
- Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation (“NIPRO”) for multiple biosimilar...
- 06월 09일 11:44
-
- RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
- Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The da...
- 06월 08일 11:35
-
- Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an...
- 06월 08일 11:20
-
- ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
- ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application...
- 06월 05일 17:20
-
- Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable...
- 06월 05일 16:00
-
- Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/a...
- 06월 05일 15:35
-
- Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
- Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and exp...
- 06월 04일 15:15
-
- European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
- Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethas...
- 06월 04일 11:40
전시회
